Bellicum Announces Late-Breaking Poster Presentation On TCR Product Candidate With Activation Switch At The AACR 2016 Annual Meeting

HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company, and its collaborating investigators at Leiden University Medical Center (LUMC), have been selected for a late-breaking poster presentation of a T cell receptor (TCR) product candidate containing the proprietary MyD88/CD40 activation switch (Go-TCR™) at the AACR 2016 Annual Meeting. The conference will take place in New Orleans from April 16-20, 2016.